For example, in phase I clinical trials of advanced solid tumors and blood cancers, CC-90002, an anti-CD47 antibody, is used to block over-expressed CD47 on cancer cells, thereby inhibiting the CD47-SIRPα signaling pathway and enhancing the phagocytosis of tumor cells by macrophages [102]. Here, CD47 is linked to hematopoietic and lymphoid system neoplasm.